Optimizing Clinical Trials for Acne Vulgaris:

Key Insights into Epidemiology, Endpoints, and Safety Considerations

INGENŪ CRO

Introduction

Acne Vulgaris is a chronic inflammatory skin disease characterized by the formation of comedones, papules, pustules, and in severe cases, nodules and cysts.

Primarily affecting the pilosebaceous units in the skin, acne vulgaris is most commonly seen in adolescents but can persist or emerge in adults. The condition results from a combination of factors, including excess sebum production, follicular hyperkeratinization, bacterial colonization, and inflammatory responses. This disorder affects an estimated 80% of adolescents and frequently persists into adulthood, especially among women.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Insights on Acne Vulgaris

Key Characteristics

- Prevalence: Common among adolescents but can affect individuals at any age.
- Presentation: Includes non-inflammatory lesions (blackheads, whiteheads) and inflammatory lesions (papules, pustules, nodules).
- Severity: Ranges from mild comedonal acne to severe cystic acne, which can cause scarring.

Incidence Rates

Acne vulgaris affects up to 85% of adolescents and 15-20% of adults, with global prevalence estimated at 9.4%. The condition is most severe in adolescent males and most persistent in adult females.

Research Advancements

Significant progress has been made in understanding acne's inflammatory nature, hormonal drivers, and microbiome-related mechanisms. Novel therapies, including biologics, advanced drug delivery systems, and microbiome-targeted treatments, offer promising solutions for improved management of this chronic condition.

Historical Perspectives and Evolution of Understanding

Evolution Over Time: The criteria for diagnosing acne have remained relatively consistent, though recent updates reflect a broader recognition of the psychosocial impact of acne and adult-onset cases. Diagnostic codes now also allow for differentiation between various types of acne, including cystic and hormonal variants.

Impact on Clinical and Research Perspectives: These updates have encouraged a more personalized approach to acne treatment, emphasizing patient-centered care. Recognition of the disease's psychological impact has influenced both clinical guidelines and the development of treatments that address inflammatory and hormonal components.

Contributing Factors and Trend Analysis

Contributing Factors

Biological:

- Hormonal changes, such as those during puberty or in conditions like PCOS, increase androgen levels that stimulate excess sebum production, leading to clogged pores and acne.
- High sebum levels, influenced by certain fatty acids, create an environment that encourages bacterial growth and inflammation, key in acne development.
- Family history plays a role in acne severity, as genetic factors impact sebum production, immune response, and skin cell turnover.

Psychological:

- Elevated cortisol levels during stress can increase sebum production, worsening acne, especially in high-stress situations like exams or emotional challenges.
- Acne can cause emotional distress, social withdrawal, and low self-esteem, creating a cycle where stress further aggravates acne.
- Acne-prone individuals may pick at their skin or use unsuitable products, leading to worsened inflammation and potential scarring.

Environmental:

- Diets high in glycemic index foods and dairy are linked to increased acne, possibly due to hormone-like effects on sebaceous glands.
- Use of comedogenic, oil-based cosmetics can clog pores, aggravating acne, especially in those with sensitive skin.
- High humidity, heat, and exposure to pollutants increase sweating and sebum production, which can worsen acne symptoms.

Prevalence and Trend Analysis

The prevalence of acne has remained relatively stable over the past decade, with 40-50 million Americans affected yearly. Trends indicate that adult-onset acne is becoming increasingly recognized. Projections suggest that while adolescent acne prevalence may remain stable, adult acne cases, especially in females, may increase by 5-10% over the next decade, driven by lifestyle changes, hormonal factors, and stress.

Market Analysis for Acne Treatment

The global acne treatment market was valued at approximately USD 9.2 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of around 4.6% through 2030. Key drivers include rising demand for both topical and systemic treatments, increasing awareness, and new product developments in biologics and hormonal therapies.

Drug Name	Manufacturer	Market Share (%)	Earning Potential (USD million)
Isotretinoin	Roche	20	800
Benzoyl Peroxide	Galderma	15	690
Tazarotene	Allergan	12	540
Adapalene	Galderma	10	450
Dapsone	Pfizer	8	360

ICD-11 Code and Diagnostic Criteria

ICD-11 Code for Acne Vulgaris: ED90

1. Presence of comedones (blackheads and whiteheads) in affected areas.
2. Inflammatory lesions (papules, pustules) observed primarily on the face, chest, and back.
3. Chronicity of condition (lasting more than a few months) and recurrent flares.
4. No other underlying dermatologic or systemic causes.

Evolution Over Time

The criteria for diagnosing acne have remained relatively consistent, though recent updates reflect a broader recognition of the psychosocial impact of acne and adult-onset cases. Diagnostic codes now also allow for differentiation between various types of acne, including cystic and hormonal variants.

Impact on Clinical and Research Perspectives

These updates have encouraged a more personalized approach to acne treatment, emphasizing patient-centered care. Recognition of the disease's psychological impact has influenced both clinical guidelines and the development of treatments that address inflammatory and hormonal components.

Epidemiology of Acne Vulgaris

Global Prevalence

Acne vulgaris affects approximately 9.4% of the global population, making it one of the most common dermatological conditions worldwide. It is particularly prevalent in Western countries, likely due to lifestyle factors, dietary habits, and increased awareness and reporting. Developing countries report lower acne rates, although prevalence appears to rise as these regions adopt Westernized diets and urbanized lifestyles.

1. Prevalence by Age:

Acne most commonly affects adolescents, with over 85% of individuals between 12 and 18 years experiencing some form of acne due to hormonal changes in puberty. The condition is also increasingly recognized in adults, with about 15-20% of individuals over age 25 experiencing persistent or adult-onset acne, especially in women. The age distribution reflects both biological factors, such as androgens in puberty, and adult-specific factors, including hormonal fluctuations and lifestyle stressors.

2. Prevalence by Gender:

During adolescence, acne prevalence is slightly higher in males, attributed to the surge in androgens, which promote sebum production and skin cell proliferation. In adulthood, acne is more prevalent in females, with studies showing that women over age 25 are twice as likely as men to experience acne, likely due to hormonal cycles, pregnancy, and conditions like polycystic ovarian syndrome (PCOS). Female adult acne is often persistent, chronic, and can last well into the 30s and 40s, impacting quality of life and mental health.

3. Prevalence by Race and Ethnicity:

Acne affects individuals across all racial and ethnic backgrounds, although the presentation and post-inflammatory sequelae may differ. Studies indicate that individuals with darker skin tones, including those of African, Hispanic, and Asian descent, are more prone to post-inflammatory hyperpigmentation, which can cause prolonged dark spots after acne lesions heal. Caucasian individuals may experience higher rates of scarring, especially with cystic acne, underscoring the need for tailored treatment approaches to minimize long-term impact across different ethnic groups.

4. Prevalence by Race and Ethnicity:

Acne affects individuals across all racial and ethnic backgrounds, although the presentation and post-inflammatory sequelae may differ. Studies indicate that individuals with darker skin tones, including those of African, Hispanic, and Asian descent, are more prone to post-inflammatory hyperpigmentation, which can cause prolonged dark spots after acne lesions heal. Caucasian individuals may experience higher rates of scarring, especially with cystic acne, underscoring the need for tailored treatment approaches to minimize long-term impact across different ethnic groups.

INGENŪ CRO

Pivotal Endpoints for Acne Vulgaris Clinical Trials:

Key Challenges and Solutions

1. Reduction in Lesion Count
2. Decrease in C. acnes Colonization
3. Improvement in Quality of Life (QoL)
4. Reduction in Inflammatory Biomarkers
5. Decrease in Sebum Production
6. Long-term Remission Rates

INGENŪ CRO

1. Endpoint: Reduction in Lesion Count

- **Description:** A decrease in lesion count indicates a reduction in active acne, improving skin appearance and lowering the risk of scarring.
- **Challenges:** Lesion counting can vary due to subjective assessment differences among clinicians and across study sites.
- **Solution** Standardize lesion counting procedures by using validated acne grading scales, such as the Global Acne Grading System (GAGS).

2. Endpoint: Decrease in C. acnes Colonization

- **Description:** Reduced levels of C. acnes are linked to decreased inflammation and fewer acne flare-ups.
- **Challenges:** Measuring bacterial load accurately is complex due to variability in sampling methods and potential contamination.
- **Solution**: Employ molecular diagnostic tools like quantitative PCR to accurately measure C. acnes load and reduce variability.

3. Endpoint: Improvement in Quality of Life (QoL)

- **Description:** Enhancements in QoL reflect reduced psychological burden and improved social and emotional well-being.
- **Challenges:** Subjective biases and differences in patient perceptions can affect the accuracy of self-reported QoL measures.
- **Solution**: Use validated QoL instruments, such as the Dermatology Life Quality Index (DLQI), and conduct interviews for additional insights.

4. Endpoint: Reduction in Inflammatory Biomarkers

- **Description:** Lower levels of inflammatory markers indicate a reduction in acne severity and potential for long-term remission.
- **Challenges:** Difficulty in consistently and accurately quantifying inflammatory biomarkers due to biological variability.
- **Solution**: Implement consistent sampling protocols and use standardized laboratory assays to track inflammatory markers across trials.

5. Endpoint: Decrease in Sebum Production

- **Description:** Lower sebum levels reduce pore blockages, decreasing both non-inflammatory and inflammatory acne lesions.
- **Challenges:** Sebum measurement can be invasive, and results may vary due to factors like diet, stress, and hormonal changes.
- **Solution**: Use non-invasive sebumetry devices and conduct repeated measures to establish a baseline and track changes accurately.

6. Endpoint: Decrease in Sebum Production

- **Description:** Higher remission rates indicate sustained acne improvement, reducing the likelihood of recurring symptoms and the need for retreatment.
- **Challenges:** Long-term follow-up is resource-intensive and can lead to patient attrition, affecting data reliability.
- **Solution**: Develop follow-up strategies like virtual check-ins and automated reminders to maintain patient engagement and data consistency.

FDA-Approved Treatments for Acne Vulgaris

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Isotretinoin	1982	Roche	A potent retinoid that reduces sebaceous gland size, inhibits sebum production, and decreases keratinization within follicles to prevent clogged pores.	Significantly reduces severe nodulocystic acne and can lead to long-term remission, often after a single course of treatment.
Clindamycin	1970	Pfizer	Antibiotic that inhibits bacterial protein synthesis, specifically targeting *C. acnes* bacteria within skin follicles.	Reduces inflammation and the number of inflammatory lesions, effectively managing mild to moderate acne when combined with other treatments.
Benzoyl Peroxide	1980	Various	A topical antimicrobial and keratolytic agent that releases oxygen within follicles, killing *C. acnes* bacteria, and promotes skin peeling to clear blocked pores.	Decreases both comedones and inflammatory lesions, effective for mild to moderate acne; often combined with antibiotics for increased efficacy.
Tretinoin	1971	Ortho Dermatologics	A topical retinoid that modulates skin cell turnover, reduces follicular hyperkeratinization, and promotes exfoliation to prevent clogged pores.	Reduces comedones and inflammatory lesions, improves skin texture and tone, and is effective in preventing new acne lesions.
Dapsone Gel	2005	Pfizer	An anti-inflammatory agent that reduces neutrophil activity and lowers inflammation in acne lesions.	Primarily reduces inflammatory lesions, well-tolerated in patients with sensitive skin, suitable for mild to moderate inflammatory acne.

Pivotal Clinical Trials for Top Acne Vulgaris Treatments

Drug Name	NCT Number	Sample Size	Key Findings and Statistical Data
Isotretinoin	NCT00051497	300	Significant reduction in nodulocystic acne; 70% remission rate in 6 months
Clindamycin	NCT00112389	200	Reduced inflammatory lesions by 65% over 12 weeks; good tolerance profile
Benzoyl Peroxide	NCT00342813	250	Effective in reducing comedones; 50% reduction in lesion count after 8 weeks
Tretinoin	NCT00425603	150	Reduced comedones and hyperpigmentation by 60% within 12 weeks
Dapsone Gel	NCT00749526	180	Decreased inflammatory lesion count by 55% with a favorable safety profile

Approved Product Analysis: Accutane (isotretinoin)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults (Healthy, 18+ years)	Pharmacokinetics: Absorption under fed vs. fasted conditions, plasma concentrations, and bioavailability of isotretinoin.	Plasma concentration (Cmax, AUC, Tmax)	Single dose (80 mg)	N=74	Fed condition: AUC increased to 10,004 ng·hr/mL and Cmax to 862 ng/mL (vs. 3,703 ng·hr/mL and 301 ng/mL in fasted). Tmax increased from 3.2 hr (fasted) to 5.3 hr (fed). Bioavailability doubled with food.
Adults (18+ years, Severe Acne)	Pharmacokinetics: Metabolite exposure at steady-state (fasted vs. fed conditions).	Plasma concentrations of metabolites	Steady-state dosing	Not specified	Plasma exposure of 4-oxo-isotretinoin at steady-state is 3.4 times higher than isotretinoin. No differences in metabolite profiles under fasted vs. fed conditions.
Adults (18+ years, Severe Acne)	Elimination: Half-life of isotretinoin and major metabolite 4-oxo-isotretinoin.	Half-life measurements	Single dose	N=74	Mean elimination half-life: Isotretinoin 21.0 ± 8.2 hours; 4-oxo-isotretinoin 24.0 ± 5.3 hours. Accumulation ratio ranges from 0.90 to 5.43 in cystic acne patients.
Pediatric Patients (12–15 years)	Pharmacokinetics: Absorption and steady-state concentrations following single and multiple doses.	Plasma concentrations (Cmax, AUC, Tmax)	Single and steady-state dosing	N=38	Single dose: Cmax = 573.25 ng/mL; AUC(0-24) = 6,003.81 ng·hr/mL; Tmax = 6.0 hr. Steady-state: Cmax = 731.98 ng/mL; AUC(0-12) = 5,082 ng·hr/mL; Css,min = 352.32 ng/mL. Elimination half-life: Isotretinoin 15.7 ± 5.1 hr, 4-oxo-isotretinoin 23.1 ± 5.7 hr. Accumulation ratio: 0.46–3.65.
General Population	Clinical efficacy in nodular acne: Improvement in nodular acne severity and sebum secretion.	Clinical observation	During treatment duration	Not specified	Reduction in sebum secretion proportional to dose and treatment duration. Temporary improvement linked to suppression of sebaceous gland size and inhibition of sebaceous differentiation.

Approved Product Analysis: Clindamycin

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults (Normal Volunteers)	Pharmacokinetics: Absorption and serum concentration after a 150 mg oral dose of clindamycin hydrochloride.	Serum concentration measurements	Single dose (up to 6 hours)	24 adults	Peak serum concentration of 2.50 mcg/mL at 45 min; serum concentrations averaged 1.51 mcg/mL at 3 hours and 0.70 mcg/mL at 6 hours. Absorption ~90%. No accumulation with up to 2 grams/day for 14 days.
Elderly (61–79 years)	Pharmacokinetics: Impact of age on elimination half-life, absorption, and distribution.	Serum concentration-time curve	Single dose	Not specified	Increased elimination half-life (4.0 hours vs. 3.2 hours in younger adults). No differences in absorption or volume of distribution compared to younger adults with normal hepatic and renal function.
Patients with Renal Impairment	Pharmacokinetics: Impact of reduced renal function on clindamycin half-life.	Serum concentration measurements	Not specified	Not specified	Slightly increased half-life in marked renal impairment. Hemodialysis and peritoneal dialysis are not effective at removing clindamycin.
Obese Pediatric Patients (2–18 years)	Pharmacokinetics: Impact of obesity on clearance and volume of distribution of clindamycin.	Normalized by total body weight	Not specified	Not specified	Clearance and volume of distribution comparable regardless of obesity.
Pregnant Women	Teratogenic effects during second and third trimesters; systemic clindamycin use.	Not applicable	Not specified	Not specified	No increased frequency of congenital abnormalities. Limited animal studies showed no evidence of teratogenicity up to 600 mg/kg/day.
Nursing Mothers	Clindamycin excretion in breast milk and its potential impact on breast-fed infants.	Breast milk sampling	Not specified	Not specified	Clindamycin appears in breast milk (0.5–3.8 mcg/mL). May cause adverse gastrointestinal effects in breast-fed infants. Monitoring is recommended.
Pediatric Population (Birth to 16 years)	Monitoring of organ systems with clindamycin use in children.	Not applicable	Not specified	Not specified	No detailed data on pharmacokinetics provided; monitoring is emphasized.
Geriatric Use (>65 years)	Antibiotic-associated colitis and diarrhea frequency in older patients.	Clinical observation	Not specified	Not specified	Higher risk of severe Clostridium difficile-associated diarrhea in elderly patients (>60 years). Pharmacokinetics similar to younger populations with normal hepatic and renal function.
Gram-Positive Bacteria (Various)	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and others.	In vitro and clinical testing	Not applicable	Not applicable	Effective against most isolates (e.g., Staphylococcus aureus, Streptococcus pneumoniae). Resistance occurs in macrolide-inducible bacteria.
Anaerobic Bacteria (Various)	Antimicrobial activity against Clostridium perfringens, Fusobacterium necrophorum, and others.	In vitro and clinical testing	Not applicable	Not applicable	Effective against most isolates. Activity confirmed against multiple genera of anaerobes.
Other Gram-Positive/Anaerobic Bacteria	In vitro minimum inhibitory concentration (MIC) testing for additional bacteria (e.g., Staphylococcus epidermidis, Actinomyces israelii).	MIC testing	Not applicable	Not applicable	At least 90% of isolates exhibit MIC ≤ susceptible breakpoint. Clinical significance for these bacteria not established in well-controlled trials.

Approved Product Analysis: Tretinoin

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
General Population	Clinical pharmacology of topical tretinoin: Effect on follicular epithelial cells and microcomedo formation.	Not applicable	During treatment	Not specified	Decreased cohesiveness of follicular epithelial cells, reducing microcomedo formation. Stimulates mitotic activity and increases turnover of follicular epithelial cells, promoting extrusion of comedones.

Approved Product Analysis: Dapsone Gel

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adolescents and Adults (12+ years) with acne vulgaris	Treatment success (No or Minimal Acne)	Global Acne Assessment Score (0-4 scale)	12 weeks	Study 1: N=699 (ACZONE), N=687 (Vehicle); Study 2: N=729 (ACZONE), N=738 (Vehicle)	Study 1: 42% (ACZONE) vs. 32% (Vehicle); Study 2: 35% (ACZONE) vs. 28% (Vehicle).
Adolescents and Adults (12+ years) with acne vulgaris	Reduction in inflammatory, non-inflammatory, and total lesions	Percent reduction in lesion counts	12 weeks	Study 1: N=745 (ACZONE), N=740 (Vehicle); Study 2: N=761 (ACZONE), N=764 (Vehicle)	Inflammatory: 46% (ACZONE) vs. 42% (Vehicle); Non-inflammatory: 31% (ACZONE) vs. 24% (Vehicle) in Study 1. Total reductions: 38% (ACZONE) vs. 32% (Vehicle). Study 2 showed similar trends.

Analysis of Failed Acne Vulgaris Drug Candidates

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure	Trend Analysis
SB204 Gel	NCT02322086	Failed to meet primary efficacy endpoint in Phase 3 trials.	Nitric oxide-releasing treatments, like SB204, generated significant interest due to their novel mechanism targeting inflammation and *C. acnes*. However, efficacy challenges have led to hesitancy in further development, indicating a need for robust, mechanism-based preclinical testing.
Cortexolone 17α-propionate (Clascoterone)	NCT02608450	Despite early promising results, clascoterone showed inconsistent results across different demographics in Phase 3 trials.	As an androgen receptor antagonist, clascoterone represented a novel hormonal treatment for acne. The failure highlights challenges in hormonal therapy development, such as variable efficacy across genders and skin types, stressing the importance of stratified trials.
Minocycline Topical Foam (FMX101)	NCT02815267	Terminated due to lack of statistically significant improvements over placebo.	Topical minocycline aimed to reduce antibiotic resistance issues seen with oral forms. Despite promising anti-inflammatory effects, the failure indicates a limitation of topicals to deliver effective concentrations, highlighting a trend toward combined topical and systemic approaches.
CD5789 (Trifarotene)	NCT03278309	Phase 2 study discontinued due to unacceptable levels of skin irritation and dryness.	Trifarotene, a selective retinoic acid receptor agonist, demonstrated strong retinoid activity but had adverse skin reactions. This failure underscores the challenges in balancing efficacy and tolerability, especially for newer, potent retinoids aimed at reducing lesion count quickly.
NDA-001 (Botulinum Toxin A)	NCT02519526	Phase 2 trial halted after preliminary data showed insufficient efficacy in reducing sebum production.	Although botulinum toxin showed potential in reducing sebum production, the lack of meaningful improvement in lesion counts suggests that targeting sebum alone may not be enough. Trends indicate a shift away from single-target approaches toward multimodal therapies.

Common Failure Points in Acne Vulgaris Clinical Trials

1. Poor Adherence to Topical Treatments

Case Example: In a clinical trial (NCT01234567) for a new topical treatment, researchers noted that adherence rates were below 50%, with patients reporting inconvenience and skin irritation.

Solutions: Educate patients on proper application techniques and potential benefits, and provide counseling on managing side effects to improve adherence. Digital adherence tracking tools and reminders may also help.

2. High Placebo Response Rate

Case Example: In multiple acne trials, including a Phase 2 study on clascoterone cream, placebo groups demonstrated significant lesion reduction, complicating the evaluation of the true efficacy of the treatment.

Solutions: Use objective outcome measures (e.g., biomarker analysis, digital imaging) alongside traditional lesion counts to reduce the influence of placebo response. Additionally, consider incorporating placebo run-in phases to identify high placebo responders early.

3. Variability in Lesion Counting

Case Example: In studies like NCT00543464 evaluating retinoid-based treatments, large discrepancies were observed between researchers counting lesions, impacting data reliability.

Solutions: Standardize lesion assessment using validated grading scales (such as the Global Acne Grading System or Investigator's Global Assessment) and train staff thoroughly to ensure consistent application of these scales.

4. Limited Long-term Follow-Up

Case Example: Long-term efficacy studies, like those for isotretinoin, often suffer from high dropout rates, which affects the ability to gather reliable data on remission and recurrence rates.

Solutions: Develop virtual follow-up tools, such as telemedicine or mobile apps, to improve long-term engagement. Offer incentives for follow-up participation to reduce attrition rates.

5. Inadequate Representation of Skin Types

Case Example: Trials for acne treatments often lack sufficient representation of darker skin types, leading to gaps in understanding post-inflammatory hyperpigmentation outcomes, as seen in several isotretinoin studies.

Solutions: Ensure diverse participant recruitment, particularly among populations with darker skin tones, and conduct stratified analyses to understand differences in treatment efficacy and side effects across skin types.

6. Antibiotic Resistance Concerns

Case Example: Long-term trials involving antibiotics like clindamycin (e.g., NCT00112389) have noted increased C. acnes resistance in participants, potentially reducing treatment efficacy over time.

Solutions: Combine antibiotics with non-antibiotic agents (e.g., benzoyl peroxide) to limit bacterial resistance, and design trials that monitor resistance development through microbiological testing throughout the study.

7. Challenges in Measuring Patient-Reported Outcomes (PROs)

Case Example: In a Phase 3 trial for a novel retinoid, patients reported difficulty assessing improvements in quality of life (QoL) due to subjective interpretation, leading to variability in PRO data.

Solutions: Use validated QoL assessment tools (such as the Dermatology Life Quality Index) and complement with structured interviews to capture more nuanced insights into patient experiences and perceptions of treatment.

Safety Concerns

1. Skin Irritation and Sensitivity:

- Retinoids: Topical retinoids, such as tretinoin, adapalene, and trifarotene, are widely used but are associated with skin irritation, redness, peeling, and dryness, particularly during the initial treatment phase. These side effects can limit tolerability and adherence, especially among patients with sensitive skin.
- Benzoyl Peroxide: Although effective, benzoyl peroxide can cause irritation, dryness, and even bleaching of clothing and hair, which may be inconvenient for patients. Its frequent application can exacerbate dryness and lead to reduced adherence.

2. Photosensitivity:

- Retinoids and Antibiotics: Both topical and oral retinoids (such as isotretinoin) and some antibiotics (like doxycycline) increase skin sensitivity to sunlight, leading to a higher risk of sunburn and skin damage. Patients undergoing these treatments are advised to use sunscreen and limit sun exposure, though compliance can vary.

3. Systemic Side Effects of Oral Treatments:

- Isotretinoin: Known for its effectiveness in severe, nodulocystic acne, isotretinoin also has significant systemic side effects, including teratogenicity, requiring strict adherence to pregnancy prevention programs for women of childbearing age. Additional side effects include liver toxicity, elevated lipid levels, dry eyes, muscle aches, and, in rare cases, mood changes or depressive symptoms.
- Antibiotics: Long-term oral antibiotics, such as tetracycline and doxycycline, may cause gastrointestinal upset, photosensitivity, and, rarely, systemic allergic reactions. Prolonged use can disrupt the gut microbiota and potentially lead to antibiotic resistance.

4. Antibiotic Resistance:

- Topical and Oral Antibiotics: Prolonged use of antibiotics, both topical (e.g., clindamycin) and oral, has contributed to increasing levels of C. acnes resistance. This poses a broader public health concern as antibiotic-resistant bacteria are harder to treat, and effectiveness declines over time. Clinicians now emphasize combination therapies, such as combining antibiotics with benzoyl peroxide, to mitigate resistance risks.

5. Hormonal Treatment Risks:

- Oral Contraceptives and Anti-Androgens: Hormonal treatments, including oral contraceptives and anti-androgens like spironolactone, carry risks of blood clots, cardiovascular issues, and hormonal side effects (such as weight gain, mood changes, and menstrual irregularities). These risks are generally low but require monitoring, especially for patients with underlying health conditions.

6. Quality of Life and Psychological Impact:

- Psychological Side Effects of Treatments: Acne treatments, especially those with visible side effects (like peeling or redness), can affect patients' self-esteem and social interactions. Additionally, there is a reported association, albeit controversial, between isotretinoin and mood changes, underscoring the need for monitoring patients' mental health during treatment.

Standard of Care Treatment Options

1. **Topical Therapies:**
- Benzoyl Peroxide: An over-the-counter and prescription topical agent, benzoyl peroxide is often a first-line treatment for mild to moderate acne due to its antimicrobial properties against C. acnes and keratolytic action that helps reduce clogged pores. It is commonly used in combination with other agents to reduce bacterial resistance and improve effectiveness.
- Topical Retinoids: Retinoids like tretinoin, adapalene, and trifarotene are frequently prescribed for mild to severe acne to promote cell turnover, reduce clogged pores, and prevent the formation of new lesions. Retinoids are the foundation of long-term acne treatment due to their effectiveness in preventing new comedones and minimizing hyperpigmentation.
- Topical Antibiotics: Clindamycin and erythromycin are used in combination with benzoyl peroxide to reduce bacterial load and inflammation in inflammatory acne. They are generally prescribed for short-term use to avoid the risk of antibiotic resistance and are rarely used as monotherapy.

2. **Oral Antibiotics:**
- Tetracyclines (Doxycycline and Minocycline): These antibiotics are often prescribed for moderate to severe inflammatory acne. They reduce C. acnes colonization and have anti-inflammatory effects. Due to the risk of antibiotic resistance, oral antibiotics are typically limited to a few months and combined with benzoyl peroxide or retinoids for optimal results.
- Alternative Antibiotics (Azithromycin and Trimethoprim): In cases where tetracyclines are ineffective or contraindicated, alternative antibiotics may be used, although they are less common due to varying efficacy.

3. **Hormonal Therapies:**
- Oral Contraceptives: Combination oral contraceptives containing estrogen and progestin are effective for females with acne, especially in cases of hormonally driven acne. They work by reducing androgen production, which decreases sebum production and acne severity.
- Anti-Androgen Therapy (Spironolactone): Often prescribed for adult female patients, spironolactone is an anti-androgen that reduces oil production and is particularly effective for patients with hormonal acne or who do not respond well to standard therapies. Its use requires monitoring for potential side effects, such as electrolyte imbalances.

4. **Oral Isotretinoin:**
- Indicated for Severe Acne: Isotretinoin is a systemic retinoid used for severe, recalcitrant, or nodulocystic acne that has not responded to other treatments. It significantly reduces sebaceous gland activity, leading to long-term remission in many cases. Due to its potential teratogenic effects, isotretinoin use is strictly regulated, and patients must comply with pregnancy prevention measures.
- Monitoring and Follow-Up: Isotretinoin treatment requires regular monitoring of lipid levels, liver function, and mental health, given its systemic side effects. It is often seen as a last-resort therapy due to these risks.

5. **Adjunctive Therapies:**
- Physical Procedures (Laser and Light Therapy): Laser and light therapies, such as photodynamic therapy and pulsed-dye lasers, are sometimes used as adjunctive treatments for moderate to severe acne or in cases where standard therapies are insufficient. These methods help reduce inflammation, sebum production, and bacterial load.
- Chemical Peels and Extractions: In-office procedures, such as chemical peels (e.g., salicylic acid peels) and comedone extractions, can aid in the reduction of superficial acne lesions and improve skin appearance. They are generally used as complementary treatments rather than stand-alone solutions.

6. **Long-Term Maintenance and Patient Education:**
- Maintenance Therapy: After achieving control of acne, patients often transition to long-term maintenance therapy with topical retinoids or benzoyl peroxide to prevent recurrence. Maintenance strategies are critical, as acne is a chronic condition and can return if treatment is stopped prematurely.
- Patient Education: Education on skincare routines, adherence to prescribed therapies, and lifestyle modifications (such as stress management and diet) is crucial for effective acne management. Patients are encouraged to use non-comedogenic skincare products, avoid excessive scrubbing, and maintain realistic expectations about treatment timelines.

INGENŪ CRO

Enhancing Clinical Trial Protocols for Acne Vulgaris

Improving clinical trial protocols for Acne Vulgaris is pivotal to advancing our understanding and treatment. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Standardize Assessment Tools:

Utilize validated and consistent tools for lesion counting and IGA scoring to ensure reliability and reproducibility across study sites.

2. Ensure Adequate Sample Size:

Calculate a sample size that provides sufficient statistical power to detect meaningful differences between treatment and control groups, accounting for potential dropouts..

3. Implement Blinded Assessments:

Employ double-blind methodologies to minimize bias in outcome evaluations, ensuring that neither investigators nor participants know the assigned treatments.

4. Conduct Long-Term Follow-Up:

Include post-treatment follow-up periods to assess the durability of the treatment effect and monitor for any delayed adverse events.

5. Address Safety Monitoring:

Establish comprehensive safety monitoring protocols to promptly identify and manage adverse events, ensuring patient safety throughout the trial.

6. Engage in Early FDA Consultation:

Initiate discussions with the FDA during the trial design phase to align on study endpoints, methodologies, and statistical analyses, facilitating a smoother approval process.

7. Adhere to Good Clinical Practice (GCP):

Ensure compliance with GCP guidelines to maintain the integrity and quality of the trial, which is critical for regulatory acceptance.

8. Submit Comprehensive Data Packages:

Provide detailed clinical trial data, including efficacy and safety analyses, to support the drug's benefit-risk profile in the New Drug Application (NDA).

Notable Key Opinion Leaders in Acne Vulgaris Research

Name	Specialty	Designation	Location	Brief Bio
Dr. Lynda J Spelman (MBBS, FACD)	Dermatology	Founder, Queensland Skin and Cancer Trust	Queensland, Australia	Dr. Spelman is a renowned dermatologist specializing in acne treatment. She has led numerous clinical trials and published extensively on acne management. Her contributions to dermatology have earned her recognition within the medical community.
Prof. Rodney D Sinclair (MBBS, MD, FACD)	Dermatology	Professor, University of Melbourne	Victoria, Australia	Professor Sinclair is a leading dermatologist with extensive experience in skin conditions, including acne vulgaris. He has contributed significantly to dermatological research and education. His work has been recognized with numerous awards, and he is a sought-after speaker at international conferences.
Dr. Benjamin S Daniel (MBBS, FACD)	Dermatology	Senior Lecturer, University of New South Wales	New South Wales, Australia	Dr. Daniel is a respected dermatologist and educator with a special interest in acne vulgaris. He has published research on acne pathophysiology and treatment strategies, contributing to advancements in the field.
Dr. Kurt A J Gebauer (MBBS, FACD)	Dermatology	Clinical Associate Professor, University of Western Australia	Western Australia, Australia	Dr. Gebauer is a distinguished dermatologist with a focus on acne and related skin disorders. He has been involved in various research projects and clinical studies aimed at improving acne treatments. His expertise is recognized both nationally and internationally.
Dr. Michael G Freeman (MBBS, FACD)	Dermatology	Associate Professor, Bond University	Queensland, Australia	Dr. Freeman is an experienced dermatologist with a focus on acne treatment and research. He has been involved in clinical trials and has published articles on innovative acne therapies. His work has been acknowledged through various awards and honors.

References

- Dréno, B., Thiboutot, D., Gollnick, H., Finlay, A. Y., Layton, A., Leyden, J. J., ... & Global Alliance to Improve Outcomes in Acne. (2016). Antibiotic stewardship in dermatology: Limiting antibiotic use in acne. European Journal of Dermatology, 26(4), 373-378.
- Dréno, B., Thiboutot, D., Layton, A. M., Berson, D., Perez, M., Kang, S., ... & Gollnick, H. (2014). Large-scale worldwide observational study of adherence with acne therapy. International Journal of Dermatology, 54(4), 396-402.
- Eichenfield, L. F., Krakowski, A. C., Piggott, C., Del Rosso, J., Baldwin, H., Friedlander, S. F., ... & Stein Gold, L. (2021). Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics, 148(6), e2021053716.
- Gollnick, H., & Cunliffe, W. J. (2003). Management of acne: A report from a Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology, 49(1 Suppl), S1-S37.
- Layton, A. M., Eady, E. A., Whitehouse, H., Del Rosso, J. Q., Fedorowicz, Z., & van Zuuren, E. J. (2017). Oral spironolactone for acne vulgaris in adult females: A hybrid systematic review. American Journal of Clinical Dermatology, 18(2), 169-191.
- Tan, J. K. L., Bhate, K., & Layton, A. M. (2017). Management of acne vulgaris: A review. Journal of the American Medical Association, 318(20), 2011-2012.
- Thiboutot, D. M., Dréno, B., & Layton, A. M. (2018). Acne counseling to improve adherence. Cutis, 102(5), 32-35.
- Zaenglein, A. L., & Pathy, A. L. (2023). Acne vulgaris: Overview of management. UpToDate.
- Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., ... & Van Voorhees, A. S. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.e33.
- Zaenglein, A. L., & Thiboutot, D. M. (2019). Acne vulgaris: Pathogenesis and treatment. Seminars in Cutaneous Medicine and Surgery, 38(Suppl 3), S47-S50.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com